CANF

Can-Fite BioPharma Ltd.

• TipRanks·09/29 10:35

  Can-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged

• Benzinga·09/28 18:00

  Can-Fite BioPharma Files Prospectus For Offering ~6.599M Ordinary Shares On Behalf Of Selling Shareholders

• TipRanks·09/09 11:27

  Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant

• Seeking Alpha·09/09 05:07

  Can-Fite Biopharma GAAP EPS of -$1.24, revenue of $0.2M

• NASDAQ·09/08 15:06

  Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds Expectations

• TipRanks·09/08 12:46

  Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs

• Benzinga·09/08 12:30

  Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY

• TipRanks·09/03 16:01

  Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing

• Benzinga·09/02 17:06

  12 Health Care Stocks Moving In Wednesday's Intraday Session

• Benzinga·09/02 15:48

  Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study

• NASDAQ·09/02 14:28

  Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges

• TipRanks·09/02 14:17

  Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline

• Benzinga·09/02 13:05

  Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price

• Benzinga·09/02 12:07

  12 Health Care Stocks Moving In Wednesday's Pre-Market Session

• TipRanks·09/02 11:41

  Can-Fite reports longer-than-anticipated survival observed in Namodenoson study